NeuroOne Medical Technologies (NMTC) Expected to Post Earnings on Thursday

NeuroOne Medical Technologies (NASDAQ:NMTC) is anticipated to issue its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect NeuroOne Medical Technologies to post earnings of ($0.5833) per share and revenue of $2.5470 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. On average, analysts expect NeuroOne Medical Technologies to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ NMTC opened at $1.56 on Tuesday. NeuroOne Medical Technologies has a fifty-two week low of $1.42 and a fifty-two week high of $6.96. The company has a market cap of $13.57 million, a PE ratio of -1.84 and a beta of 0.61. The business has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $3.88.

Insider Transactions at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, Director Mark Christianson sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the sale, the director directly owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.80% of the stock is owned by corporate insiders.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new position in NeuroOne Medical Technologies during the fourth quarter valued at approximately $36,000. Susquehanna International Group LLP purchased a new stake in NeuroOne Medical Technologies in the 3rd quarter worth approximately $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies during the 2nd quarter worth approximately $51,000. Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies during the 1st quarter worth approximately $84,000. Finally, Virtu Financial LLC acquired a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter worth approximately $88,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

Wall Street Analyst Weigh In

NMTC has been the topic of several research analyst reports. Weiss Ratings raised shares of NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. LADENBURG THALM/SH SH lifted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $11.67.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.